MediGene progresses on two fronts
This article was originally published in Scrip
MediGene has seen a modest uptick in its share price after announcing progress with two of its products. The company's share stood at €1.09 in mid-afternoon trading on the Frankfurt stock exchange on 12 December (up from €1.06 on 9 December and €1.02 on 8 December) after announcing that its genital wart ointment Veregen had been accepted for review in 17 European countries. The product, which was previously known as Polyphenon E and is derived from green tea leaves, is already available in the US, Germany and Austria, and has been granted approval in Spain, with launch there expected next year.